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Abstract The class 1A phosphatidylinositol 3-kinase enzymes
consist of a number of heterodimeric complexes of regulatory
and catalytic subunits and have been implicated in a number
of cellular responses. While platelet-derived growth factor
(PDGF)-induced chemotaxis of human vascular smooth muscle
cells (HVSMC) is inhibited by both wortmannin and LY294002,
DNA synthesis is only inhibited by LY294002. Serum-induced
DNA synthesis however is inhibited by LY294002, wortmannin
and rapamycin. Similarly PDGF-induced protein kinase B
(PKB) activation is inhibited by LY294002 but not by wortman-
nin or rapamycin. In conclusion PDGF-induced DNA synthesis
appears to occur through a phosphatidylinositol 3-kinase (PI3-
K)-dependent, but wortmannin-insensitive, PKB/Akt pathway.
7 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Phosphatidylinositol 3-kinase (PI3-K) is a lipid kinase
which speci¢cally phosphorylates phosphatidylinositol (PI),
phosphatidylinositol 4-phosphate (PIP) or phosphatidylinosi-
tol 4,5-bisphosphate (PIP2) on the D3 position of the inositol
ring resulting in the production of phosphatidylinositol
3-phosphate [PI(3)P], phosphatidylinositol 3,4-bisphosphate
[PI(3,4)P2] and phosphatidylinositol 3,4,5-trisphosphate [PI-
(3,4,5)P3]. Although PI(3)P has been shown to occur consti-
tutively in cells PI(3,4)P2 and PI(3,4,5)P3 are only detected in
stimulated cells suggesting a role for these inositol phospho-
lipids as intracellular mediators [1].
The PI3-K family of enzymes generally consist of a hetero-
dimeric complex of regulatory (55^150 kDa) and catalytic
(100^200 kDa) subunits and can be divided into classes with
respect to structure, regulation and lipid speci¢city. The class
1A PI3-K enzymes consist of an 85 kDa regulatory subunit
(K, L and Q isoforms), a 110 kDa catalytic subunit (K, L and N
isoforms) and use PIP2 as a lipid substrate [2]. The regulatory
subunit contains several de¢ned functional domains which
allow it to bind to other cellular proteins resulting in the
build-up of a signalling complex. The SH2 domains in this
regulatory subunit bind to and are phosphorylated by a range
of activated growth factor receptors including the platelet-de-
rived growth factor (PDGF) receptor and the insulin receptor
[3,4]. Although not essential for PI3-K activity, several studies
have demonstrated that growth factor-stimulated tyrosine
phosphorylation of the regulatory subunit correlates well
with enzyme activation [3,5,6].
The major role of vascular smooth muscle cells (VSMC) in
vivo is contraction and when fully di¡erentiated these cells
have a low proliferative index. Following injury or disease
however these take on a synthetic phenotype which is capable
of both chemotaxis and growth [7]. A similar dedi¡erentia-
tion is seen in VSMC in culture suggesting that this condition
may represent a model of injury. While the culture of animal-
derived VSM cells is commonly used for experimental pur-
poses work from this group has consistently demonstrated
that data from animal cells do not always provide an accurate
re£ection of signalling mechanisms in human VSM cells [6,
8^10].
Class 1A PI3-K enzymes have recently been implicated in
the chemotaxis [11], growth [12] and contractility [13] of sev-
eral types of cell and have also been shown to act as a survival
factor in a large number of cells [14,15].
Recent data from our laboratory have demonstrated that
PDGF di¡erentially induces chemotaxis and DNA synthesis
in human VSMC (HVSMC) with the PDGFL receptor acting
as both a positive and a negative modulator of chemotaxis.
Low concentrations of PDGF (1^10 ng/ml) induce chemotaxis
but very little DNA synthesis whereas high concentrations
(s 30 ng/ml) promote DNA synthesis but inhibit chemotaxis.
Di¡erential patterns of tyrosine phosphorylation are also in-
duced by these di¡erent concentrations of PDGF indicating
that di¡erent signalling pathways are activated although in-
creased tyrosine phosphorylation of an 85 kDa band is seen
following stimulation with concentrations of PDGF that stim-
ulate either chemotaxis or DNA synthesis suggesting the in-
volvement of PI3-K [9].
Data presented here demonstrate that while PDGF-induced
chemotaxis is inhibited by both of the commercially available
PI3-K inhibitors, LY294002 and wortmannin, DNA synthesis
appears to occur through a novel PI3-K-dependent but wort-
mannin-insensitive pathway.
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2. Materials and methods
2.1. Materials
Cell culture plastics, media, supplements and PDGF were obtained
from Life Technologies (Paisley, UK). Foetal calf serum (FCS) was
obtained from M.B. Meldrum Ltd (Bourne End, UK). Bovine serum
albumin fraction V was purchased from Boehringer Mannheim
(Lewes, UK). BCA protein assay kits were obtained from Pierce
Warriner (Chester, UK). Hybond C nitrocellulose, enhanced chemi-
luminescence reagents and streptavidin complex were obtained from
Amersham (Buckinghamshire, UK). All antibodies were obtained
from TCS (Buckingham, UK). All other reagents were obtained
from Sigma (Poole, UK).
2.2. VSMC culture
Human vascular smooth muscle was obtained from saphenous vein
of patients undergoing cardiovascular surgery. Tissues were surplus to
requirements, and their use conformed to the guidelines of our local
ethics committee. VSMC were cultured using an explant technique as
previously described [16] and were routinely used at third passage.
VSMC were cultured in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) bu¡ered with 25 mmol/l HEPES and supplemented with
15% (vol/vol) FCS, 4 mmol/l 1-alanyl-1-glutamine (glutamax-I), pen-
icillin (100 U/ml), streptomycin (100 Wg/ml), and gentamicin (25 Wg/
ml). Cell cultures were maintained in a humidi¢ed atmosphere of 5%
CO2 (vol/vol) in air at 37‡C. Identity of the cells as VSMC was
routinely checked by immunocytochemical studies for SM K-actin
staining.
2.3. Chemotaxis
Chemotaxis assays were performed in modi¢ed Boyden chambers as
previously described [8,9]. Brie£y the cell suspension (2.25U105 cells/
ml) was preincubated in the presence or absence of the PI3-K inhib-
itors LY294002 and wortmannin for 30 min prior to the migration
assay. The cell suspension was separated from the chemoattractant (2
ng/ml PDGF) by gelatin-coated polycarbonate ¢lters and the cham-
bers were incubated for 5 h at 37‡C prior to ¢xing in absolute ethanol
and staining with 1% toluidine blue.
2.4. DNA synthesis
DNA synthesis was determined by measuring the incorporation of
[3H]thymidine into acid-insoluble material as previously described [8].
Cells were maintained in serum-free medium for a period of 5 days
prior to the assay. Quiescent cells were preincubated in the presence
or absence of inhibitors (10 WM LY294002, 100 nM wortmannin, 100
nM rapamycin, 30 WM PD98059) for 30 min prior to stimulation
with either PDGF (30 ng/ml) or 15% FCS. [3H]thymidine was added
to the cells after 24 h and the stimulation terminated after a further
6 h.
2.5. Cell stimulation
This was performed as previously described [6,10]. Brie£y HVSMC
were subcultured and plated onto Petri dishes at a known density
(1 000 000 cells/dish) and allowed to attach for 24 h in DMEM sup-
plemented with 15% (vol/vol) FCS. Cells were then washed twice with
phosphate bu¡ered saline (PBS) and maintained in serum-free me-
dium for a period of 5 days. Quiescent cells were then stimulated
with PDGF (30 ng/ml) for a period of 30 min at 37‡C. Following
stimulation cells were washed twice with ice-cold PBS and scraped
into 1 ml of ice-cold lysis bu¡er (50 mmol/l Tris (pH 7.4); 150
mmol/l NaCl; 1 mmol/l ethyleneglycol-bis-(L-aminoetylether)-
N,N,NP,NP-tetraacetic acid (EGTA); 1% (vol/vol) NP-40; 0.25% so-
dium deoxycholate; 1 mmol/l sodium £uoride, sodium orthovanadate,
phenymethylsulphonyl £uoride; 1 Wg/ml aprotinin, pepstatin, leupep-
tin). The lysate was allowed to stand on ice for 10 min prior to
centrifugation (14 000 rpm, 15 min, 4‡C). The resulting supernatants
were used for protein measurement.
2.6. Immunoprecipitation
A known concentration of cellular protein (approximately 100 Wg)
was removed from all samples and precleared for 1 h with albumin-
agarose prior to incubation with the anti-phosphotyrosine antibody
PY-20 (1 Wg antibody/100 Wg protein) for 3 h at 4‡C. Immunopreci-
pitates were captured on protein A-agarose in the manner previously
described [6].
2.7. Immunoblotting
Immunoblotting was performed in the manner previously described
[6,10]. Brie£y proteins were separated on 10% sodium dodecyl sul-
phate^polyacrylamide gels prior to transfer to nitrocellulose using a
Bio-Rad wet gel transfer system. Following successful transfer nitro-
cellulose blots were blocked in 5% bovine serum albumin (BSA) for
1 h and washed three times in Tris bu¡ered saline containing 0.05%
Tween 20 (TTBS) prior to probing with primary antibody for 1 h.
Blots were washed several times in TTBS before being probed with
the appropriate secondary antibody and developed using enhanced
chemiluminescence.
2.8. Statistical analysis
With the exception of cell signalling studies where data were ex-
pressed as % basal phosphorylation stimulated data were de¢ned as
100% and all experimental data expressed as meanRS.E.M. in rela-
tion to this. Statistical di¡erences between means in terms of dose-
dependent e¡ects were compared using a Friedman non-parametric
analysis of variance (ANOVA) for multiple repeated measures. A
value of P9 0.05 was considered signi¢cant.
Fig. 1. E¡ect of PI3-K inhibitors on PDGF-induced cell chemotaxis. A: Histogram shows the e¡ect of increasing concentrations of LY294002
on PDGF-induced cell chemotaxis. Data are expressed as a percentage of the stimulated response which was taken to be 100% and represent
the meanRS.E.M. of experiments using four separate cell strains. * represents a P value 6 0.05. B: Histogram shows the e¡ect of increasing
concentrations of wortmannin on PDGF-induced cell chemotaxis. Data are expressed as a percentage of the stimulated response which was tak-
en to be 100% and represent the meanRS.E.M. of experiments using four separate cell strains. * represents a P value 6 0.05.
FEBS 27912 8-12-03
J.S. Lymn et al./FEBS Letters 555 (2003) 591^596592
3. Results
3.1. E¡ect of PI3-K inhibitors on HVSMC chemotaxis
Treatment of HVSMC with both the PI3-K inhibitors,
LY294002 and wortmannin, prior to their exposure to a di-
rected gradient of PDGF (2 ng/ml) resulted in a concentra-
tion-dependent decrease in the ability of these cells to migrate
in response to PDGF (Fig. 1).
3.2. E¡ect of PI3-K inhibitors on HVSMC DNA synthesis
Treatment with LY294002 resulted in a concentration-de-
pendent reduction in the ability of HVSMC to synthesise
DNA in response to PDGF but treatment with wortmannin
had no signi¢cant e¡ect on DNA synthesis induced by PDGF
in HVSMC (Fig. 2). Neither replacing the media with fresh
wortmannin-containing media nor topping up the wortman-
nin concentration 6 hourly resulted in any additional inhibi-
tion of PDGF-induced DNA synthesis (data not shown). In
light of these results the e¡ects of PI3-K inhibitors on serum
(15%)-induced DNA synthesis of HVSMC were investigated.
Treatment with 10 WM LY294002 resulted in complete inhi-
bition of serum-induced DNA synthesis while treatment with
100 mM wortmannin also resulted in a moderate but signi¢-
cant inhibition of DNA synthesis (Fig. 3).
Fig. 2. E¡ect of PI3-K inhibitors on PDGF-induced DNA synthesis. A: Histogram shows the e¡ect of increasing concentrations of LY294002
on PDGF-induced [3H]thymidine incorporation in HVSMC. Data are expressed as a percentage of the stimulated response which was taken to
be 100% and represent the meanRS.E.M. of experiments using four separate cell strains. * represents a P value 6 0.05. B: Histogram shows
the e¡ect of increasing concentrations of wortmannin on PDGF-induced [3H]thymidine incorporation in HVSMC. Data are expressed as a per-
centage of the stimulated response which was taken to be 100% and represent the meanRS.E.M. of experiments using four to 16 separate cell
strains. * represents a P value 6 0.05.
Fig. 3. E¡ect of PI3-K inhibitors on serum-induced DNA synthesis.
Histogram shows the e¡ect of 10 WM LY294002 and 100 nM wort-
mannin on PDGF-induced [3H]thymidine incorporation in HVSMC.
Data are expressed as a percentage of the stimulated response which
was taken to be 100% and represent the meanRS.E.M. of experi-
ments using four separate cell strains. * represents a P value 6 0.05.
Fig. 4. E¡ect of PI3-K inhibitors on PDGF-stimulated p85 phos-
phorylation. Histogram shows the e¡ect of 100 nM wortmannin
and 10 WM LY294002 on tyrosine phosphorylation of the p85 regu-
latory subunit of PI3-K. Phosphorylation of control, unstimulated
cells was taken to be 100% and all other data were normalised
against this. Data represent the meanRS.E.M. of two separate cell
strains. Representative Western blot is shown above the histogram.
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3.3. E¡ect of PI3-K inhibitors on PDGF-stimulated p85
phosphorylation
Western blotting for the p85 regulatory subunit of PI3-K
following immunoprecipitation of tyrosine-phosphorylated
proteins demonstrated that high-dose PDGF stimulated a
3-fold increase in the phosphorylation state of this subunit.
This PDGF-stimulated phosphorylation was not a¡ected by
treatment with wortmannin but was inhibited by treatment
with LY294002 (Fig. 4).
3.4. Role of p70S6kinase in HVSMC DNA synthesis
In order to determine whether the wortmannin-insensitive
pathway required activation of p70S6kinase the e¡ect of rapa-
mycin (1^100 nM) on PDGF-induced DNA synthesis in
HVSMC was investigated. Rapamycin did not a¡ect the level
of PDGF-induced DNA synthesis at any concentration. Se-
rum-induced DNA synthesis however, was signi¢cantly inhib-
ited by 1 nM rapamycin (48R 8% of the stimulated response).
The level inhibition of serum-induced DNA synthesis was not
a¡ected by increasing concentrations of the inhibitor up to
100 nM (Fig. 5).
3.5. Role of mitogen-activated protein kinase (MAPK) in
HVSMC DNA synthesis
In order to determine whether the wortmannin-insensitive
pathway activated by PDGF involves the activation of
MAPK the e¡ect of the MEK inhibitor PD98059 on
PDGF-induced DNA synthesis was investigated. PD98059 re-
sulted in a concentration-dependent inhibition of both PDGF-
and serum-induced DNA synthesis albeit to di¡ering extents.
PDGF-induced DNA synthesis was almost completely inhib-
ited by 30 WM PD98059 while serum-induced DNA synthesis
was only partially inhibited (30 WM PD98059 ^ 56R4% of
stimulated response) (Fig. 6).
3.6. E¡ect of inhibitors on the activation of downstream targets
Protein kinase B (PKB) or Akt1 is a 60 kDa serine/threo-
nine protein kinase which has been identi¢ed as being a down-
stream target of PI3-K. PDGF stimulation of HVSMC re-
sulted in a 2.5-fold increase in the level of activation of
PKB, as determined by the increase in the level of phosphor-
ylation of serine 473. This activation of PKB/Akt was com-
pletely inhibited by treatment with 10 WM LY294002 but un-
a¡ected by 100 nM wortmannin, 100 nM rapamycin or 30 WM
PD98059 (Fig. 7A).
P70S6kinase may also be a possible downstream target of
PI3-K. PDGF stimulation of HVSMC did not however re-
sult in any signi¢cant increase in the activity of p70S6kinase
(as measured by phosphorylation of threonine 412) above
control levels, although treatment with rapamycin signi¢-
Fig. 5. E¡ect of p70S6kinase inhibitor on PDGF- and serum-induced
DNA synthesis. Histogram shows the e¡ect of 100 nM rapamycin
on PDGF- and serum-induced [3H]thymidine incorporation in
HVSMC. Data are expressed as a percentage of the stimulated re-
sponse which was taken to be 100% and represent the meanR
S.E.M. of experiments using ¢ve to six separate cell strains. * repre-
sents a P value 6 0.05.
Fig. 6. E¡ect of MEK inhibitor on PDGF- and serum-induced DNA synthesis. A: Histogram shows the e¡ect of increasing concentrations of
PD98059 on PDGF-induced [3H]thymidine incorporation in HVSMC. Data are expressed as a percentage of the stimulated response which was
taken to be 100% and represent the meanRS.E.M. of experiments using ¢ve separate cell strains. * represents a P value 6 0.05. B: Histogram
shows the e¡ect of increasing concentrations of PD98059 on serum-induced [3H]thymidine incorporation in HVSMC. Data are expressed as a
percentage of the stimulated response which was taken to be 100% and represent the meanRS.E.M. of experiments using six separate cell
strains. * represents a P value 6 0.05.
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cantly reduced p70S6kinase activity to below basal levels (Fig.
7B).
4. Discussion
Data presented here suggest that PDGF stimulates DNA
synthesis in HVSMC via a novel PI3-K-dependent but wort-
mannin-insensitive pathway which is distinct from that stimu-
lated by serum. Similarly the PI3-K isoforms involved in this
signalling pathway can be di¡erentiated from those involved
in PDGF-induced chemotaxis by their sensitivity to the PI3-K
inhibitors, LY294002 and wortmannin.
Our initial concern with respect to the PDGF-induced
DNA synthesis data was that wortmannin activity was being
lost over the course of the assay although a number of groups
had previously demonstrated inhibition of growth factor-in-
duced DNA synthesis by wortmannin using similar assay con-
ditions [5,17^19]. However, since regular addition of fresh
wortmannin did not result in any additional inhibition of
PDGF-induced DNA synthesis and serum-induced DNA syn-
thesis was signi¢cantly inhibited by wortmannin, it is unlikely
that loss of wortmannin activity accounts for the results. The
incomplete inhibition of serum-induced DNA synthesis by
wortmannin correlates well with data obtained from vascular
endothelial cells [20] and probably results from activation of
the pathway stimulated by PDGF that is present in the serum.
Further to this we investigated whether the di¡erential ef-
fects of wortmannin and LY294002 on PDGF-stimulated
DNA synthesis were speci¢cally related to activation of PI3-
K isoforms. To this end we determined the e¡ect of these
inhibitors on the PDGF-stimulated tyrosine phosphorylation
of the p85 regulatory subunit of PI3-K which we have pre-
viously shown to be an accurate re£ection of growth factor-
induced enzyme activation in these cells [6]. High-dose PDGF
resulted in an approximately 3-fold increase in the level of p85
tyrosine phosphorylation, which was not a¡ected by wort-
mannin but was inhibited by LY294002, suggesting that
high-dose PDGF does selectively activate a wortmannin-in-
sensitive isoform of PI3-K in HVSMC.
A number of signalling proteins have been reported to lie
downstream of PI3-K activation with the most well estab-
lished being the serine threonine kinases p70S6kinase and
PKB/Akt [21,22]. In an e¡ort to further clarify the mecha-
nisms involved in our observation we investigated the possible
roles of these signalling proteins in the wortmannin-insensitive
signalling pathway. The p70S6kinase inhibitor rapamycin did
not result in any inhibition of PDGF-induced DNA synthesis,
although it did result in a signi¢cant inhibition of serum-in-
duced DNA synthesis. These data suggest that the wortman-
nin-insensitive cell signalling pathway is independent of the
activation of p70S6kinase. Indeed cell stimulation with PDGF
did not result in activation of p70S6kinase as measured by phos-
phorylation-speci¢c antibodies. The involvement of rapamy-
cin with serum-stimulated DNA synthesis correlates well with
data from a variety of vascular endothelial cell lines [20], while
the lack of involvement of p70S6kinase in PDGF-stimulated
DNA synthesis has previously been demonstrated in both
rat and human aortic cells [23].
PDGF stimulation did, however, result in a 2.5-fold activa-
tion/phosphorylation of PKB/Akt, which was inhibited by
LY294002 but not by wortmannin, indicating that PDGF-
induced DNA synthesis in HVSMC occurs via a PI3-K- and
PKB-dependent pathway.
PDGF-induced DNA synthesis was inhibited by the MEK
inhibitor PD98059 suggesting that activation of ERK1/ERK2
is necessary for this wortmannin-insensitive PDGF-induced
signalling pathway. The lack of e¡ect of PD98059 on PKB/
Akt phosphorylation, coupled with the complete inhibition of
DNA synthesis by LY294002, suggests that activation of
ERK1/ERK2 may occur downstream of PKB in this PI3-K-
dependent signalling pathway. Similar observations have been
reported in both Chinese hamster ovary (CHO) and Cos7 cells
[24,25] and a physical association between PKB and Raf has
been demonstrated in A7r5 cells [26].
Fig. 7. E¡ect of inhibitors on PDGF-induced activation of PKB. A: Histogram shows the activation of PKB/Akt (meanRS.E.M.) as deter-
mined by densitometric analysis of the anti-phospho Akt antibody. Phosphorylation of control, unstimulated cells was taken to be 100% and
all other data were normalised against this. Data represent the meanRS.E.M. of three separate strains. * represents a P value 6 0.05. Repre-
sentative Western blot is shown above the histogram. 100 nM wortmannin (W), 10 WM LY294002 (LY), 30 WM PD98059 (PD) and 100 nM ra-
pamycin (R). B: Histogram shows activation of p70S6kinase as determined by densitometric analysis of the anti-phospho-p70S6kinase antibody.
Phosphorylation of control, unstimulated cells was taken to be 100% and all other data were normalised against this. Data represent the
meanRS.E.M. of three separate cell strains. Representative Western blot is shown above the histogram.
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This report clearly demonstrates PDGF-induced stimula-
tion of DNA synthesis through an LY294002-sensitive but
wortmannin-insensitive pathway. While both inhibitors lose
speci¢city at high concentrations a recent report has suggested
that LY294002 may inhibit casein kinase 2 (CK2) at concen-
trations similar to those required for PI3-K inhibition [27].
There are, however, no data to suggest that CK2 can activate
PKB/Akt or that it is involved in growth factor-induced DNA
synthesis [28] indicating that the results seen here are likely to
occur through a PI3-K/PKB-dependent pathway. While
LY294002 and wortmannin have previously been thought to
show relatively little selectivity for PI3-K isoforms a novel
wortmannin-insensitive class 2 PI3-K has been reported [29].
Similarly Coulonvol et al. demonstrated di¡erential sensitiv-
ities of PI3-K-dependent p70S6kinase activity to wortmannin
and LY294002 [18].
In summary, these data indicate that PDGF induces DNA
synthesis of HVSMC through a novel PI3-K-dependent but
wortmannin-insensitive pathway. The multiplicity of PI3-K
regulatory and catalytic subunit isoforms gives rise to the
possibility of a variety of distinct p85p110 heterodimeric com-
plexes which have been suggested to be involved in speci¢c
cellular responses [30^32]. It is likely that it is this variety
of heterodimers that gives rise to the di¡erential ability of
PI3-K inhibitors to inhibit speci¢c cellular responses. The de-
velopment of novel selective inhibitors could represent a ma-
jor pharmacological advance in the treatment of human dis-
ease.
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